Zenas BioPharma, Inc. (NASDAQ:ZBIO) Receives Average Rating of “Moderate Buy” from Brokerages

Zenas BioPharma, Inc. (NASDAQ:ZBIO) has been given an average rating of “Moderate Buy” by the nine analysts that are presently covering the company, MarketBeat.com reports. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and six have issued a buy rating on the company. The average twelve-month price objective among brokers that have covered the stock in the last year is $44.2857.

A number of research analysts recently issued reports on ZBIO shares. Wall Street Zen upgraded shares of Zenas BioPharma from a “strong sell” rating to a “sell” rating in a report on Saturday, May 16th. Weiss Ratings restated a “sell (d-)” rating on shares of Zenas BioPharma in a report on Friday, March 27th. Zacks Research raised shares of Zenas BioPharma from a “strong sell” rating to a “hold” rating in a research note on Friday, May 15th. Morgan Stanley lifted their price target on shares of Zenas BioPharma from $21.00 to $22.00 and gave the company an “equal weight” rating in a research note on Thursday, May 14th. Finally, HC Wainwright reaffirmed a “buy” rating on shares of Zenas BioPharma in a research note on Wednesday, June 3rd.

Zenas BioPharma Stock Up 0.8%

Shares of NASDAQ ZBIO opened at $17.61 on Tuesday. The stock has a market cap of $1.11 billion, a P/E ratio of -2.08 and a beta of -0.71. The firm has a 50 day moving average price of $19.49 and a 200 day moving average price of $25.08. The company has a debt-to-equity ratio of 1.04, a quick ratio of 11.94 and a current ratio of 11.94. Zenas BioPharma has a 52-week low of $8.91 and a 52-week high of $44.60.

Zenas BioPharma (NASDAQ:ZBIO) last issued its quarterly earnings data on Wednesday, May 13th. The company reported ($1.46) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.47) by $0.01. During the same quarter last year, the firm posted ($0.80) EPS. Analysts expect that Zenas BioPharma will post -4.47 EPS for the current year.

Insider Buying and Selling at Zenas BioPharma

In related news, CEO Leon O. Moulder, Jr. purchased 60,000 shares of the business’s stock in a transaction on Monday, May 18th. The shares were purchased at an average price of $16.88 per share, with a total value of $1,012,800.00. Following the completion of the purchase, the chief executive officer owned 96,928 shares in the company, valued at $1,636,144.64. This represents a 162.48% increase in their position. The acquisition was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Fairmount Funds Management Llc purchased 150,000 shares of the business’s stock in a transaction on Tuesday, March 31st. The stock was bought at an average cost of $20.00 per share, for a total transaction of $3,000,000.00. Following the purchase, the director owned 2,359,025 shares of the company’s stock, valued at approximately $47,180,500. This represents a 6.79% increase in their position. The disclosure for this purchase is available in the SEC filing. Over the last quarter, insiders have purchased 273,768 shares of company stock valued at $5,150,198. 22.00% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the stock. GF Fund Management CO. LTD. bought a new position in Zenas BioPharma in the fourth quarter valued at approximately $38,000. Quarry LP lifted its stake in Zenas BioPharma by 34.5% in the third quarter. Quarry LP now owns 1,134 shares of the company’s stock valued at $25,000 after buying an additional 291 shares in the last quarter. Russell Investments Group Ltd. bought a new position in Zenas BioPharma in the third quarter valued at approximately $30,000. CWM LLC lifted its position in shares of Zenas BioPharma by 48.3% in the fourth quarter. CWM LLC now owns 2,178 shares of the company’s stock worth $79,000 after purchasing an additional 709 shares in the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. bought a new stake in shares of Zenas BioPharma in the fourth quarter worth $95,000.

About Zenas BioPharma

Zenas BioPharma, Inc is a clinical-stage biotechnology company focused on the discovery and development of novel therapies in oncology and infectious diseases. The company’s proprietary platform integrates structure-guided design, computational modeling and high-throughput screening to address challenging protein-protein interactions. Zenas BioPharma is advancing multiple preclinical and clinical-stage candidates aimed at providing new treatment options where current modalities may be limited by efficacy or safety concerns.

Founded in 2021 and headquartered in Cambridge, Massachusetts, Zenas BioPharma was built to streamline the drug discovery process from target identification through to IND-enabling studies.